Key result
ALPK3 variants, particularly truncating mutations, are associated with both hypertrophic and dilated cardiomyopathies, contributing to phenotypic variability and severe clinical outcomes.
Why the study?
Clinical genetic testing fails to identify a causative mutation in approximately 40% of hypertrophic cardiomyopathy cases, suggesting the involvement of non-sarcomeric genes such as ALPK3.
ALPK3 variants are a significant genetic cause of non-sarcomeric cardiomyopathies, highlighting the need for genetic screening in diverse populations to improve diagnosis and management.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2025) conducted a review in Hypertrophic and Dilated Cardiomyopathies. ALPK3 variants was evaluated. ALPK3 variants, particularly truncating mutations, are associated with both hypertrophic and dilated cardiomyopathies, contributing to phenotypic variability and severe clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: